As EVP, Managing Director of Client Partnerships at RevHealth, I’ve had the privilege of working closely with pharmaceutical innovators to bring life-changing therapies to market. At RevHealth, our mission is simple yet ambitious: to support pharmaceutical brands in driving better patient outcomes through smart, strategic commercialization. As we look ahead to ASCO 2025 in Chicago, I’m energized by the opportunity to explore how scientific breakthroughs—and emerging AI trends—are reshaping the oncology landscape, especially in cancer impacting women’s health.
Each year, ASCO sets the stage for the future of cancer care. This year, I’m particularly excited about advancements in ovarian and breast cancer treatments, from biomarker-driven therapies to novel combinations in later-line settings. These are not just scientific milestones—they're commercial game-changers.
I’m also drawn to sessions on AI-powered clinical decision support and patient stratification tools, which are pushing the boundaries of precision oncology. For pharmaceutical manufacturers and brand managers, these innovations mean earlier market access, more targeted messaging, and a deeper alignment with the evolving standard of care.
In my role leading Client Services at RevHealth, I bring a unique lens to ASCO—one focused not only on scientific relevance but also strategic impact. I’ll be listening for insights that signal how pharma brands can differentiate in a crowded oncology market, accelerate time to value, and engage oncologists in innovative ways.
We often serve as the connective tissue between medical innovation and commercial execution. Whether it’s shaping launch narratives, building omnichannel engagement plans, or enabling field teams with real-world tools, we turn complex science into clear market opportunity.
Why does this matter commercially? Because the themes emerging at ASCO will directly impact how pharma teams position their products, prioritize investments, and compete in an increasingly data-driven environment. AI isn’t just transforming R&D—it’s enabling more personalized HCP outreach, earlier patient identification, and smarter resource allocation across the product lifecycle.
For brands preparing to launch or expand in oncology, the lessons from ASCO 2025 will help define not just what they say, but how and when they say it—and to whom.
As I walk the halls of McCormick Place, I’ll be looking to gather actionable insights that help our clients future-proof their oncology portfolios. I’d love to hear what’s on your radar, what challenges you're solving for, and how we might collaborate to unlock new value in cancer care.
Here’s to a transformative ASCO and an even more impactful future for oncology innovation.